Injectable GHK-Cu was in Category 2 the more restrictive category for substances with "significant safety concerns." Its removal from Category 2 is the more positive development, as it signals the FDA no longer considers injectable GHK-Cu to carry the safety risk level that warranted Category 2 placement
This anti-inflammatory action proves particularly valuable for disc-related pain, where inflammation around compressed nerve roots contributes significantly to symptoms
Cancer Biol Ther 2:S105-114 Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B (2017) The different mechanisms of cancer drug resistance: a brief review
As we age, the bodys capacity to produce glutathione decreases
Forslund 2015
Cell Reports , 44 (1), 115125 Yuan, H., Wu, X., Wu, Q., Chatoff, A., Megill, E., Gao, J., Huang, T., Duan, T., Yang, K., Jin, C., Yuan, F., Wang, S., Zhao, L., Zinn, P